Answers are grounded in this paper and cite their sources.
Objective To evaluate the dihydrofolate reductase inhibitory activity and anticancer properties of certain polyphenolic compounds such as cyanidin, delphinidin, formononetin, naringenin, and gallic acid by using an integrated in silico and in vitro study on human breast and colon cancer cells. Method For molecular docking studies, the compound was docked against the target protein DHFR (PDB ID: 1RX2) using the Maestro protocol in Schrödinger software to study the binding affinity and interaction pattern. Cytotoxicity studies were performed using the MTT assay in the cell lines MCF-7, MDA-MB-231, HCT-116, and HT-29. Mechanistic studies included Annexin V FITC/PI apoptosis assay, DCFH-DA-based intracellular ROS level estimation, Western blotting to study the expression of DHFR, and colony formation assay. Results The docking study showed the strong binding affinity of cyanidin (−9.721) to DHFR, except for the standard cocrystal. Among phytoconstituents, the lowest IC₅₀ values were observed for cyanidin in the in vitro study. The treatment showed significant increase in ROS and apoptosis in a dose-response manner ( p < 0.0001). Strong correlation was observed between ROS and apoptosis ( r = 0.91). Western blot results showed significant downregulation of DHFR protein expression, especially in HCT-116 cells. Strong correlation was observed between DHFR and apoptosis ( r = −0.88). Results showed significant inhibitory effect in colony formation. Conclusion The findings show that cyanidin has potent DHFR-targeting anticancer activity mediated by ROS-induced apoptosis and suppression of clonogenic survival. These findings emphasize the potential of polyphenolic compounds, such as cyanidin, as anticancer agents that target DHFR.
No takes yet. Share an insight, caveat, or question.
Saudar et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: